Founded out of the Stanford laboratory of Steve Quake, Bluestar Genomics is an early cancer detection company focused on the development and commercialization of non-invasive epigenomic tests to detect cancer through a standard blood draw, earlier than existing methods and when the disease is still treatable.
epigenomics approach to
analyzing active biology
reinventing liquid biopsy
Non-invasive “liquid biopsy,” using cell-free DNA and high throughput genetic analyses, traditionally focuses on detecting sequence differences. This has limited big data applications to clinical conditions where such differences exist.
With the addition of epigenomics, we escape the limitations of sequence alone, providing new disease and clinical information to solve broader healthcare needs.
The company uses its one-of-a-kind epigenomic platform that combines best-in-class bioinformatics and biomedical technologies to analyze individuals’ changing biology that is yet to produce symptoms.
Song et al, Cell Research 2017
Song et al, PNAS 2016
bioRxiv Preprint, 2018
medRxiv Preprint, 2020
Bluestar Genomics presents new data showing its liquid biopsy test detects pancreatic cancer signal >> Read Press Release
Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA >> Download PDF
Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board >> Read Press Release
Bluestar Genomics Receives FDA Breakthrough Device Designation for First-of-Its-Kind Pancreatic Cancer Screening Test >> Read Press Release
In the first steps toward innovative liquid biopsy applications, Bluestar Genomics reports epigenomics results stratifying pancreatic cancer patients from cell free DNA samples. >> Read Press Release
Stanford Spinout Bluestar Genomics Develops Epigenomic Method to Detect Pancreatic Cancer. >> Read GenomeWeb Article
Aiming to improve early diagnosis of cancer using noninvasive methods, Bluestar Genomics presents data demonstrating the feasibility of a novel blood test for earlier detection and classification of multiple cancers. >> Read Press Release
Bluestar Genomics shares new noninvasive data for earlier cancer detection with promising performance at 11th CNAPs International Symposium. >> Read Press Release
Bluestar Genomics’ Breakthrough Study Highlights Promising Data for Multi-Cancer Detection from a Single Blood Draw. >> Read Press Release
- Cell/Tissue Specificity
Identify changes in specific organs using a systemic sample
- Biological Activity
Detect biological activity and gene expression
- Disease Biomarkers
Reveal the presence and progression of disease
- Drug Development
Improve therapy selection, efficacy and safety monitoring
- Health Monitoring
Assess individual organ systems and biological functions
- Non-Invasive Sampling
Avoid biopsy, surgery or direct tissue requirements
- Systems Biology
Uncover the hidden interactions of multiple systems simultaneously
great chemistry | big data | systems biology
We look for extraordinary lifelong learners with a passion and growth mindset for the above disciplines, and for combining biological ingenuity with AI and data analysis, to improve healthcare outcomes. Led by a team with decades of experience bringing products from concept to market, we have offices in the San Francisco Bay Area and San Diego.